Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001337553-22-000033
Filing Date
2022-08-05
Accepted
2022-08-04 18:35:37
Documents
69
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q aeri-20220630.htm   iXBRL 10-Q 1489430
2 EX-31.1 aeri6302022ex311.htm EX-31.1 12404
3 EX-31.2 aeri6302022ex312.htm EX-31.2 12376
4 EX-32.1 aeri6302022ex321.htm EX-32.1 7222
5 EX-32.2 aeri6302022ex322.htm EX-32.2 7222
11 GRAPHIC aeri-20220630_g1.jpg GRAPHIC 13674
12 GRAPHIC aeri-20220630_g2.jpg GRAPHIC 13447
  Complete submission text file 0001337553-22-000033.txt   6911695

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT aeri-20220630.xsd EX-101.SCH 43061
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT aeri-20220630_cal.xml EX-101.CAL 62030
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT aeri-20220630_def.xml EX-101.DEF 240873
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT aeri-20220630_lab.xml EX-101.LAB 578212
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT aeri-20220630_pre.xml EX-101.PRE 383135
63 EXTRACTED XBRL INSTANCE DOCUMENT aeri-20220630_htm.xml XML 1170832
Mailing Address 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703
Business Address 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703 (919) 237-5300
AERIE PHARMACEUTICALS INC (Filer) CIK: 0001337553 (see all company filings)

EIN.: 203109565 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36152 | Film No.: 221138130
SIC: 2836 Biological Products, (No Diagnostic Substances)